INVESTOR NOTICE: Khang & Khang LLP Announces the Filing of a Securities Class Action Lawsuit against Lipocine Inc. and Reminds Investors with Losses to Contact the Firm

IRVINE, CA / ACCESSWIRE / July 21, 2016 / Khang & Khang LLP (the “Firm”) announces that a class action lawsuit has been filed against Lipocine Inc. (“Lipocine” or the “Company”) (NASDAQ: LPCN). Investors who purchased or otherwise acquired shares between June 30, 2015 and June 28, 2016 inclusive (the “Class Period”), are encouraged to contact the Firm prior to the August
30, 2016 lead plaintiff motion deadline.

If you purchased shares of Lipocine during the Class Period, please contact Joon M. Khang, Esquire, of Khang & Khang, 18101 Von Karman Avenue, 3rd Floor, Irvine, CA 92612, by telephone: (949) 419-3834, or by e-mail at joon@khanglaw.com.

There has been no class certification in this case. Until certification occurs, you are not represented by an attorney. You may choose to take no action and remain a passive class member.

According to the complaint, the Company made false and/or misleading statements and/or failed to disclose that: Lipocine’s filing of its New Drug Application to the U.S. Food and Drug Administration for LPCN 1021 (the Company’s lead product candidate) contained deficiencies; and as a result, Lipocine’s statements about its business and operations were false and misleading and/or lacked a reasonable basis. When this information was released, investors suffered losses.

If you wish to learn more about this lawsuit, or if you have any questions concerning this notice or your rights, please contact Joon M. Khang, a prominent litigator for almost two decades, by telephone: (949) 419-3834, or by e-mail at joon@khanglaw.com.

This press release may constitute Attorney Advertising in some jurisdictions.

Contacts

Joon M. Khang, Esq.
Telephone: 949-419-3834
Facsimile: 949-225-4474
joon@khanglaw.com

SOURCE: Khang & Khang LLP

ReleaseID: 442683